AXSM vs BIIB: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BIIB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AXSM and BIIB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AXSM and BIIB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Axsome Therapeutics is a US-listed (Nasdaq: AXSM) central nervous system biopharmaceutical company built around approved products and a late-stage pipeline. Its flagship is Auvelity (dextromethorphan-bupropion), an oral NMDA-receptor modulator for major depressive disorder that has become the primary growth engine, plus Sunosi (solriamfetol) for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea, and Symbravo (meloxicam-rizatriptan) for acute migraine. The pipeline includes AXS-12 (reboxetine) filed with the FDA for cataplexy in narcolepsy, and earlier-stage assets such as AXS-20 (balipodect), a PDE10A inhibitor for schizophrenia and Tourette syndrome.

Full AXSM guide

Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases.

Full BIIB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AXSM drivers: Auvelity revenue ramp; Label and indication expansion.
• BIIB drivers: Leqembi Alzheimer's ramp; Rare-disease and new-product portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Axsome remains unprofitable, reporting a Q1 2026 net loss of roughly $64.5M (about $1.26 per share), so the equity depends on future growth rather than current earnings. For BIIB, the legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AXSM if you believe its drivers more; BIIB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AXSM and BIIB guides.

AXSM. AXSM trades at a large-cap valuation despite still running net losses, so the multiple reflects expected growth and pipeline optionality rather than current profitability. The key figures to watch are Auvelity's quarterly sales trajectory and the path toward operating breakeven. Analysts broadly rate the stock favorably, but published targets vary widely and are not guarantees.

BIIB. Biogen trades at a low double-digit forward earnings multiple, well below the drug-manufacturer industry median, reflecting a shrinking legacy base and turnaround uncertainty. Q1 2026 earnings beat expectations on cost discipline and Leqembi momentum, but management still guides full-year revenue down a mid-single-digit percentage. The valuation prices in doubt that new launches will outrun legacy erosion.

Headline figures (approximate, JULY 2026): AXSM shows market cap ~$12.4B, revenue (q1 2026) ~$191M (up ~57% YoY), auvelity net sales (q1 2026) ~$153M (up ~59% YoY), sunosi net revenue (q1 2026) ~$34M (up ~34% YoY); BIIB shows revenue (ttm) ~$9.7B, q1 2026 revenue ~$2.5B (up ~2% YoY), q1 2026 non-gaap eps ~$3.57, market cap ~$29B.

AXSM and BIIB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AXSM and BIIB exposure against your real portfolio. It is not an investment adviser.